Pharma Giant Merck & Co. Considering 600-Job IT Hub in Austin

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-merck2.jpg" NAME"Pharma Giant Merck Considering 600-Job IT Hub in Austin" ALT"Pharma Giant Merck Considering 600-Job IT Hub in Austin"April 6, 2017By Mark Terry, BioSpace.com Breaking News Staff<A HREF"http... Source:…

Continue ReadingPharma Giant Merck & Co. Considering 600-Job IT Hub in Austin

Novogen Terminates Preclinical Program, Will Cut an Undisclosed Number of Jobs

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks3.jpg" NAME"Novogen Terminates Preclinical Program, Will Cut an Undisclosed Number of Jobs" ALT"Novogen Terminates Preclinical Program, Will Cut an Undisclosed Number of Jobs"April 6, 2017By Mark Terry, BioSpace.com... Source:…

Continue ReadingNovogen Terminates Preclinical Program, Will Cut an Undisclosed Number of Jobs

Valeant Plummets After Revealing Jaw-Dropping Payday for Its CEO

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-valeant-joseph-papa.jpg" NAME"Valeant Plummets After Revealing Jaw-Dropping Payday For Its CEO" ALT"Valeant Plummets After Revealing Jaw-Dropping Payday For Its CEO"April 5, 2017By Alex Keown, BioSpace.com Breaking News Staff... Source: BioSpace

Continue ReadingValeant Plummets After Revealing Jaw-Dropping Payday for Its CEO

Data To Be Presented At Highlighting GENFIT???s Latest Progress In NASH Biomarker Diagnostics, Identifying Novel Compounds With Potent Antifibrotic Properties, And Illustrating The Opportunities In Anti-NASH Drug Combinations

  • Post author:
  • Post category:BioPharma

  Life Sciences Jobs   ... Source: BioSpace

Continue ReadingData To Be Presented At Highlighting GENFIT???s Latest Progress In NASH Biomarker Diagnostics, Identifying Novel Compounds With Potent Antifibrotic Properties, And Illustrating The Opportunities In Anti-NASH Drug Combinations